Articles from Landmark Bio

Landmark Bio, an Artis BioSolutions company dedicated to accelerating the translation of next-generation advanced therapies from discovery to clinical and commercial production, today announced that it has secured an Advanced Research Projects Agency for Health (ARPA-H) award totaling up to $18.3 million to build an efficient, robust, and scalable continuous manufacturing platform for extracellular vesicles (EVs). The TRANSFORM EV project aims to address unmet needs in drug delivery by overcoming barriers to commercialization and broadening patient access to transformative EV-based therapeutics. This will be accomplished by establishing advanced domestic manufacturing capabilities that overcome the limitations of current low-yield, high-cost processes.

Landmark Bio, LLC today announced the initiation of a new collaboration with Mass General Brigham to provide development and manufacturing services for cell and gene therapies originating from the health system. The agreement enables Landmark Bio to support early-stage translational research and development for advanced therapies across the Mass General Brigham system, through collaboration with Mass General Brigham’s Gene and Cell Therapy Institute (GCTI). The agreement creates a path for projects aimed at accelerating therapeutic innovation from bench to bedside.

Landmark Bio™ announced today the appointment of Ran Zheng as Chief Executive Officer. Ms. Zheng is a biotechnology industry veteran who brings more than 25 years of experience in biotechnology operations across multiple geographies to Landmark Bio. Previously known as the center for advanced biological innovation and manufacturing (or “CABIM”), the mission of this newly created public benefit company is to help new therapeutics reach patients faster while strengthening Massachusetts’ position as the world’s life science capital.